keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic response

keyword
https://www.readbyqxmd.com/read/29449054/second-generation-antipsychotic-induced-mitochondrial-alterations-implications-for-increased-risk-of-metabolic-syndrome-in-patients-with-schizophrenia
#1
Giselli Scaini, João Quevedo, Dawn Velligan, David L Roberts, Henriette Raventos, Consuelo Walss-Bass
Metabolic syndrome (MetS) is seen more frequently in persons with schizophrenia than in the general population, and these metabolic abnormalities are further aggravated by second generation antipsychotic (SGA) drugs. Although the underlying mechanisms responsible for the increased prevalence of MetS among patients under SGA treatment are not well understood, alterations in mitochondria function have been implicated. We performed a comprehensive evaluation of the role of mitochondrial dysfunction in the pathophysiology of drug-induced MetS in schizophrenia...
February 12, 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29448178/modification-of-the-association-between-antipsychotic-treatment-response-and-childhood-adversity-by-mmp9-gene-variants-in-a-first-episode-schizophrenia-cohort
#2
Nathaniel McGregor, Nicole Thompson, Kevin Sean O'Connell, Robin Emsley, Lize van der Merwe, Louise Warnich
Antipsychotics remain the most effective, and wide used option for ameliorating the symptoms of schizophrenia. However, inter-individual differences in treatment outcome are vast and suggest a role for genetic and environmental factors in affording favourable outcomes. A notable epigenetic relationship which has gained considerable traction in recent literature is the way in which the severity of childhood trauma can modify associations seen between genetic variation and antipsychotic treatment response. A potential mechanism of action which may facilitate this relationship is synaptic plasticity...
February 7, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29439750/differential-neural-reward-mechanisms-in-treatment-responsive-and-treatment-resistant-schizophrenia
#3
Lucy D Vanes, Elias Mouchlianitis, Tracy Collier, Bruno B Averbeck, Sukhi S Shergill
BACKGROUND: The significant proportion of schizophrenia patients refractory to treatment, primarily directed at the dopamine system, suggests that multiple mechanisms may underlie psychotic symptoms. Reinforcement learning tasks have been employed in schizophrenia to assess dopaminergic functioning and reward processing, but these have not directly compared groups of treatment-refractory and non-refractory patients. METHODS: In the current functional magnetic resonance imaging study, 21 patients with treatment-resistant schizophrenia (TRS), 21 patients with non-treatment-resistant schizophrenia (NTR), and 24 healthy controls (HC) performed a probabilistic reinforcement learning task, utilizing emotionally valenced face stimuli which elicit a social bias toward happy faces...
February 14, 2018: Psychological Medicine
https://www.readbyqxmd.com/read/29436643/neuroprotective-effect-of-lurasidone-via-antagonist-activities-on-histamine-in-a-rat-model-of-cranial-nerve-involvement
#4
Baoming He, Liang Yu, Suping Li, Fei Xu, Lili Yang, Shuai Ma, Yi Guo
Cranial nerve involvement frequently involves neuron damage and often leads to psychiatric disorder caused by multiple inducements. Lurasidone is a novel antipsychotic agent approved for the treatment of cranial nerve involvement and a number of mental health conditions in several countries. In the present study, the neuroprotective effect of lurasidone by antagonist activities on histamine was investigated in a rat model of cranial nerve involvement. The antagonist activities of lurasidone on serotonin 5‑HT7, serotonin 5‑HT2A, serotonin 5‑HT1A and serotonin 5‑HT6 were analyzed, and the preclinical therapeutic effects of lurasidone were examined in a rat model of cranial nerve involvement...
February 13, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29433808/vmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia
#5
REVIEW
Laura M Scorr, Stewart A Factor
Tardive dyskinesia (TD) is an often disabling hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents. Although initially thought to most commonly occur with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide. Increased prescribing of these agents as well as low rates of remission have contributed to a rising prevalence of TD. Although this condition was described nearly 60 years ago, it is only within the past year that two novel therapeutic agents were FDA approved...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433074/the-relationship-between-inflammatory-state-and-quantity-of-affective-episodes-in-bipolar-disorder
#6
Robert Queissner, René Pilz, Nina Dalkner, Armin Birner, Susanne A Bengesser, Martina Platzer, Frederike T Fellendorf, Nora Kainzbauer, Simone Herzog-Eberhard, Carlo Hamm, Bernd Reininghaus, Sieglinde Zelzer, Harald Mangge, Rodrigo B Mansur, Roger S McIntyre, Hans-Peter Kapfhammer, Eva Z Reininghaus
OBJECTIVES: Immunological/inflammatory processes have been proposed to play an important role in the pathophysiology of mood disorders, including bipolar disorder (BD). The present study aimed to examine the influence of immune activation, measured on the basis of inflammatory markers, on the course of illness, proxied by the number of affective episodes, in patients with BD. METHODS: We investigated the relationship between high-sensitive CRP (hsCRP) and Interleukin 6 (IL-6), two inflammatory markers and characteristics of course of illness (e...
February 3, 2018: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29433072/pregnenolone-progesterone-allopregnanolone-pathway-as-a-potential-therapeutic-target-in-first-episode-antipsychotic-na%C3%A3-ve-patients-with-schizophrenia
#7
HuaLin Cai, Xiang Zhou, George G Dougherty, Ravinder D Reddy, Gretchen L Haas, Debra M Montrose, Matcheri Keshavan, Jeffrey K Yao
Neurosteroids are both endogenous and exogenous steroids that rapidly alter neuronal excitability through interactions with ligand-gated ion channels and other cell surface receptors. They are originated from cholesterol and have important implications for schizophrenia (SZ) pathophysiology and treatment strategies. Specifically, pregnenolone (PREG), progesterone (PROG) and allopregnanolone (ALLO) exhibit similar psychotropic properties. Using enzyme immunoassay, we compared the neurosteroids in PREG downstream pathways in plasma between healthy controls (HC, n = 43) and first-episode antipsychotic-naïve patients with SZ (FEAN-SZ, n = 53) before antipsychotic drug (APD) treatment...
February 7, 2018: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29432396/gathering-tips-from-carers-to-support-people-with-dementia-an-adaptation-of-the-top-5-program-for-community-use
#8
Kerrie Westaway, Oliver Frank, Russell Shute, Anna Moffat, Vanessa LeBlanc, Debra Rowett, Natalie Blacker, Elizabeth Roughead
AIM: Behavioral and psychological symptoms of dementia are often managed inappropriately with antipsychotic medicines. The TOP 5 program, which involves recording up to five relevant and meaningful tips that assist in personalizing care for the person with dementia, has been tested in the hospital setting and transitions of care in Australia, and has been found to be useful. Our study aimed to adapt the TOP 5 program as a strategy to support people with dementia in a primary care setting and to test the acceptability of our adapted TOP 5 program materials...
February 9, 2018: International Journal of Evidence-based Healthcare
https://www.readbyqxmd.com/read/29431144/paradigm-shift-purity-progress-and-the-origins-of-first-episode-psychosis
#9
Suze G Berkhout
First-episode psychosis has garnered significant attention and resources within mental health services in North America, Europe and Australia/New Zealand since the 1990s. Despite this widespread embrace, little scholarship exists that examines underlying concepts, ideologies and imagery embedded within the early intervention paradigm. In this paper, I offer a sociohistorical analysis of the emergence of first-episode psychosis and early intervention as entities in psychiatry, drawing on contemporary philosophical thought to explore various concepts embedded in them...
February 3, 2018: Medical Humanities
https://www.readbyqxmd.com/read/29427955/allostatic-load-is-associated-with-psychotic-symptoms-and-decreases-with-antipsychotic-treatment-in-patients-with-schizophrenia-and-first-episode-psychosis
#10
Maximus Berger, Robert-Paul Juster, Sabine Westphal, G Paul Amminger, Bernhard Bogerts, Kolja Schiltz, Sabine Bahn, Johann Steiner, Zoltan Sarnyai
Current pathophysiological models of schizophrenia suggest that stress contributes to the etiology and trajectory of the disorder. We investigated if allostatic load (AL), an integrative index of neuroendocrine, immune and metabolic dysregulation in response to chronic stress, is elevated in patients with schizophrenia (SCZ) and first-episode psychosis (FEP) and related to psychotic symptoms and social and occupational functioning. Additionally, we assessed the temporal dynamics of AL in response to treatment with second-generation antipsychotics...
February 5, 2018: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29417763/combined-treatment-with-a-selective-pde10a-inhibitor-tak-063-and-either-haloperidol-or-olanzapine-at-subeffective-doses-produces-potent-antipsychotic-like-effects-without-affecting-plasma-prolactin-levels-and-cataleptic-responses-in-rodents
#11
Kazunori Suzuki, Akina Harada, Hirobumi Suzuki, Clizia Capuani, Annarosa Ugolini, Mauro Corsi, Haruhide Kimura
Activation of indirect pathway medium spiny neurons (MSNs) via promotion of cAMP production is the principal mechanism of action of current antipsychotics with dopamine D2 receptor antagonism. TAK-063 [1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one] is a novel phosphodiesterase 10A inhibitor that activates both direct and indirect pathway MSNs through increasing both cAMP and cGMP levels by inhibition of their degradation. The activation of indirect pathway MSNs through the distinct mechanism of action of these drugs raises the possibility of augmented pharmacological effects by combination therapy...
February 2018: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/29413518/unique-effects-of-clozapine-a-pharmacological-perspective
#12
Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Green
Schizophrenia is a heterogenous and severe neuropsychiatric disorder that affects nearly 1% of the population worldwide. Antipsychotic drugs are the mainstay of treatment, but not all patients with schizophrenia respond to treatment with these agents. Clozapine, the first atypical antipsychotic, is a highly effective medication for patients with schizophrenia who do not respond to other antipsychotics. Although clozapine tends not to produce extrapyramidal symptoms, other side effects of the drug (e.g., agranulocytosis, myocarditis, seizures) limit its widespread use...
2018: Advances in Pharmacology
https://www.readbyqxmd.com/read/29410940/are-shorter-versions-of-the-positive-and-negative-syndrome-scale-panss-doable-a-critical-review
#13
REVIEW
Jean-Pierre Lindenmayer
The Positive and Negative Syndrome Scale (PANSS) is a well-established assessment tool for measuring symptom severity in schizophrenia. Researchers and clinicians have been interested in the development of a short version of the PANSS that could reduce the burden of its administration for patients and raters. The author presents a comprehensive overview of existing brief PANSS measures, including their strengths and limitations, and discusses some possible next steps. There are two available scales that offer a reduced number of original PANSS items: PANSS-14 and PANSS-19; and two shorter versions that include six items: Brief PANSS and PANSS-6...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29410938/sensitivity-of-the-positive-and-negative-syndrome-scale-panss-in-detecting-treatment-effects-via-network-analysis
#14
Farnaz Zamani Esfahlani, Hiroki Sayama, Katherine Frost Visser, Gregory P Strauss
Objective: The Positive and Negative Syndrome Scale is a primary outcome measure in clinical trials examining the efficacy of antipsychotic medications. Although the Positive and Negative Syndrome Scale has demonstrated sensitivity as a measure of treatment change in studies using traditional univariate statistical approaches, its sensitivity to detecting network-level changes in dynamic relationships among symptoms has yet to be demonstrated using more sophisticated multivariate analyses. In the current study, we examined the sensitivity of the Positive and Negative Syndrome Scale to detecting antipsychotic treatment effects as revealed through network analysis...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29408159/a-naturalistic-exploratory-study-of-obsessive-compulsive-bipolar-comorbidity-in-youth
#15
Gabriele Masi, Stefano Berloffa, Maria Mucci, Chiara Pfanner, Giulia D'Acunto, Francesca Lenzi, Francesca Liboni, Azzurra Manfredi, Annarita Milone
BACKGROUND: Growing evidence supports the comorbidity between bipolar disorder (BD) and obsessive-compulsive disorder (OCD) in children and adolescents. Our aim is to further explore clinical and treatment implications of this comorbidity, as it appears in clinical practice. METHOD: The sample included 429 consecutive patients with BD and/or OCD as primary diagnoses, followed for a mean period of 6 months (range 4-9 months), 172 with BD (102 males, mean age 13.7±2...
February 2, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29407718/neurocognitive-correlates-of-treatment-response-in-children-with-tourette-s-disorder
#16
Susanna W Chang, Joseph F McGuire, John T Walkup, Douglas W Woods, Lawrence Scahill, Sabine Wilhelm, Alan L Peterson, James Dziura, John Piacentini
This paper examined neurocognitive functioning and its relationship to behavior treatment response among youth with Tourette's Disorder (TD) in a large randomized controlled trial. Participants diagnosed with TD completed a brief neurocognitive battery assessing inhibitory functions, working memory, and habit learning pre- and post-treatment with behavior therapy (CBIT, Comprehensive Behavioral Intervention for Tics) or psychoeducation plus supportive therapy (PST). At baseline, youth with tics and Attention Deficit Hyperactivity Disorder (ADHD) exhibited some evidence of impaired working memory and simple motor inhibition relative to youth with tics without ADHD...
March 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29407591/novel-multi-target-azinesulfonamides-of-cyclic-amine-derivatives-as-potential-antipsychotics-with-pro-social-and-pro-cognitive-effects
#17
Paweł Zajdel, Tomasz Kos, Krzysztof Marciniec, Grzegorz Satała, Vittorio Canale, Krzysztof Kamiński, Małgorzata Hołuj, Tomasz Lenda, Robert Koralewski, Marek Bednarski, Leszek Nowiński, Jacek Wójcikowski, Władysława A Daniel, Agnieszka Nikiforuk, Irena Nalepa, Piotr Chmielarz, Justyna Kuśmierczyk, Andrzej J Bojarski, Piotr Popik
Currently used antipsychotics are characterized by multireceptor mode of action. While antagonism of dopamine D2 receptors is responsible for the alleviation of "positive" symptoms of schizophrenia and the effects at other, particularly serotonergic receptors are necessary for their additional therapeutic effects, there is no consensus regarding an "ideal" target engagement. Here, a detailed SAR analysis in a series of 45 novel azinesulfonamides of cyclic amine derivatives, involving the aryl-piperazine/piperidine pharmacophore, central alicyclic amine and azinesulfonamide groups has led to the selection of (S)-4-((2-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)isoquinoline (62)...
February 10, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29398916/systematic-review-of-catatonia-treatment
#18
REVIEW
Anne Cm Pelzer, Frank Mma van der Heijden, Erik den Boer
Objective: To investigate the evidence-based treatment of catatonia in adults. The secondary aim is to develop a treatment protocol. Materials and methods: A systematic review of published treatment articles (case series, cohort or randomized controlled studies) which examined the effects of particular interventions for catatonia and/or catatonic symptoms in adult populations and used valid outcome measures was performed. The articles for this review were selected by searching the electronic databases of the Cochrane Library, MEDLINE, EMBASE and PSYCHINFO...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29397899/sodium-benzoate-a-d-amino-acid-oxidase-inhibitor-added-to-clozapine-for-the-treatment-of-schizophrenia-a-randomized-double-blind-placebo-controlled-trial
#19
Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang, Hsien-Yuan Lane
BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine...
December 26, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/29392351/determination-of-plasma-concentration-reference-ranges-for-oral-aripiprazole-olanzapine-and-quetiapine
#20
Julia Korell, Bruce Green, Allan Rae, Bart Remmerie, An Vermeulen
BACKGROUND: Schizophrenia is a common disease which is commonly managed using antipsychotic medications (APS). Inadequate response and lack of adherence often prevent optimal therapeutic effectiveness. Monitoring APS concentrations can be useful to help improve outcomes for the patient. AIMS: The aim of this study was to develop "reference ranges" for oral aripiprazole, olanzapine, and quetiapine to allow clinicians to understand expected variability in patients treated with APS...
February 1, 2018: European Journal of Clinical Pharmacology
keyword
keyword
50550
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"